Hutchmed Regulatory News (HCM)

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Board Change

London: Monday, 21 February 2011:Chi-Med today announces that Mr Johnny Cheng Chig Fung has been appointed as an Executive Director of Chi-Med with effect from 18 February 2011.

Mr Cheng, aged 44, has worked in Chi-Med as Chief Financial Officer for over two years. He is a director of Hutchison MediPharma (Hong Kong) Limited and Sen Medicine Company Limited and was a director of Hutchison Healthcare Limited during 2009.

Prior to joining Chi-Med, Mr Cheng was the Vice President, Finance of Bristol Myers Squibb in China and was a director of Sino-American Shanghai Squibb Pharmaceuticals Ltd. and Bristol-Myers Squibb (China) Investment Co. Ltd. in Shanghai between late 2006 and 2008.

Mr Cheng started his career as an auditor with Price Waterhouse in Australia and then KPMG in Beijing before spending eight years with Nestle China where he was in charge of a number of finance and control functions in various operations. Mr Cheng received a Bachelor of Economics, Accounting Major from the University of Adelaide and is a member of the Institute of Chartered Accountants in Australia.

Mr Cheng holds 128,072 vested options of Chi-Med, representing approximately 0.2% of the current issued share capital of Chi-Med.

Save for the information disclosed above, there is no other information in relation to Mr Cheng required to be disclosed pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

Ends

Enquiries

About Chi-Med

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.